Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.75 |
| ▸ | HTR2A | P28223 | 16/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056329 | 0.95 | SLC6A4 (0.85) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6056311 | 0.86 | HTR2A (0.76) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5837192 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6056314 | 0.82 | SLC6A4 (0.72) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6449547 | 0.81 | SLC6A4 (0.63) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5836432 | 0.74 | HTR2A (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6056327 | 0.74 | SLC6A4 (0.74) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL13359826 | 0.73 | TAAR1 (0.60) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5838185 | 0.72 | HTR2A (1.00) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL18646614 | 0.72 | HSPB1 (0.58) | SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675582-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | Warner-Lambert Company LLC (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005025563-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | claimed |